Masimo

Masimo

Kiani, an Iranian immigrant, launched Masimo to tackle a problem he identified as an electrical engineering student: standard pulse oximeters fail on patients who are moving or have poor perfusion. Signal Extraction Technology (SET), the company's foundational platform, proved roughly 3× more reliable than competing sensors in clinical studies and became the default in roughly nine of ten top US hospitals (public record). Masimo went public in 2007 and, while officially a medical-device manufacturer, functions as a de facto technology investor: R&D spend consumed $113 million in 2023 alone, targeting adjacent spaces like noninvasive hemoglobin monitoring and home health wearables. The IP portfolio — roughly 2,500 issued and pending patents globally — is the firm's primary asset class. Its most visible application is the W1 consumer wearable, a biosensor watch that brings hospital-grade monitoring to retail channels. Clinically, Masimo devices are integrated into GE Healthcare and Philips patient monitors, supplying brain-function, respiration, and hemoglobin data beyond simple SpO2. Geographically, the company sells in over 150 countries, with assembly and technical centers in California, Switzerland, and Hong Kong. In January 2024, the US Court of Appeals for the Federal Circuit upheld the International Trade Commission's ruling that Apple infringed two Masimo patents with the blood-oxygen feature on certain Apple Watch models — forcing a temporary import ban (per Reuters, January 2024). The ruling validated Kiani's willingness to spend roughly $100 million in legal fees against the world's most valuable company. The firm operates with roughly 2,800 employees globally and continues to litigate additional patent claims while defending against proxy fights and shareholder activism regarding its corporate governance. Masimo's structural differentiator is its reliance on courtroom-enforced IP walls rather than conventional market-share battles. Unlike most med-tech firms that license quietly or settle, Masimo treats litigation as a core operational function — a posture that protects its clinical franchise with hospital incumbents while simultaneously pressuring potential consumer electronics rivals before they can scale competing health sensors.